<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075577</url>
  </required_header>
  <id_info>
    <org_study_id>EPI-7386-CS-010</org_study_id>
    <nct_id>NCT05075577</nct_id>
  </id_info>
  <brief_title>EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC</brief_title>
  <official_title>A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ESSA Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ESSA Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2 study of EPI-7386 orally administered in combination with enzalutamide in&#xD;
      subjects with mCRPC.&#xD;
&#xD;
      Phase 1 of the study will be a single-arm dose escalation study of EPI-7386 in combination&#xD;
      with a fixed dose of enzalutamide. This portion of the study will primarily evaluate the&#xD;
      safety and tolerability of the drug combination and establish the RP2CDs for EPI-7386 and&#xD;
      enzalutamide when dosed in combination. In addition, blood sampling will be conducted for PK&#xD;
      evaluation to assess the potential DDI between the two drugs.&#xD;
&#xD;
      Once the RP2CD for each drug has been established, Phase 2 of the study will commence. Phase&#xD;
      2 is a two-arm, randomized (2:1), open-label study. Approximately 120 subjects will be&#xD;
      randomized 2:1 to:&#xD;
&#xD;
        -  Group 1: EPI-7386 at the RP2CD + enzalutamide(depending on the results of the Phase 1)&#xD;
           (n=80)&#xD;
&#xD;
        -  Group 2: Enzalutamide single agent (n=40) The planned dose of enzalutamide and EPI-7386&#xD;
           for the combination arm will be those determined in the Phase 1 of this study based on&#xD;
           safety and exposure data. Subjects may remain on study treatment as long as they are&#xD;
           tolerating treatment without disease progression based on RECIST v1.1 and/or PCWG3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Incidence of Dose Limiting Toxicities</measure>
    <time_frame>Baseline to End of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for AEs [NCI CTCAE version 5.0]), timing in relation to study treatment administration, seriousness, and relationship to study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Incidence of treatment emergent adverse events</measure>
    <time_frame>Baseline to 30 days after last dose of study drug</time_frame>
    <description>Characterized by type, frequency, severity, timing, seriousness, and relationship to study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Incidence of laboratory abnormalities as a measure of safety and tolerability of EPI-7386</measure>
    <time_frame>Baseline to 30 days after last dose of study drug</time_frame>
    <description>Characterized by type, frequency, severity, timing, seriousness, and relationship to study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Changes in ECOG performance status</measure>
    <time_frame>Baseline to 30 days after last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Proportion of subjects with a prostate-specific antigen decline of &gt;50% (PSA50) at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg EPI-7386 in combination of Enzalutamide120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg EPI-7386 in combination of Enzalutamide120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg EPI-7386 in combination of Enzalutamide120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D mg EPI-7386 in combination of Enzalutamide160 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D mg EPI-7386 in combination of Enzalutamide RP2D mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Enzalutamide + EPI-7386 (Randomized 2:1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D mg EPI-7386 in combination of Enzalutamide RP2D mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Enzalutamide single agent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enzalutamide 160 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Daily oral dose of enzalutamide</description>
    <arm_group_label>Phase 2 Enzalutamide single agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-7386 with Enzalutamide</intervention_name>
    <description>Daily oral dose of EPI-7386 in combination of enzalutamide</description>
    <arm_group_label>Phase 1 Cohort 1</arm_group_label>
    <arm_group_label>Phase 1 Cohort 2</arm_group_label>
    <arm_group_label>Phase 1 Cohort 3</arm_group_label>
    <arm_group_label>Phase 1 Cohort 4</arm_group_label>
    <arm_group_label>Phase 1 Dose Expansion</arm_group_label>
    <arm_group_label>Phase 2 Enzalutamide + EPI-7386 (Randomized 2:1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma.&#xD;
&#xD;
          -  Evidence of castration-resistant prostate cancer (CRPC).&#xD;
&#xD;
          -  Presence of metastatic disease at study entry documented by 1 or more bone lesions on&#xD;
             bone scan or by soft tissue disease observed by CT/MRI.&#xD;
&#xD;
          -  Naïve to second generation anti-androgens.&#xD;
&#xD;
          -  Evidence of progressive disease defined as 1 or more Prostate Cancer Working Group 3&#xD;
             (PCWG3) criteria.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Ongoing ADT with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist&#xD;
             therapy or history of bilateral orchiectomy, with castrate level testosterone.&#xD;
&#xD;
          -  Serum testosterone ≤1.73 nmol/L (50 ng/dL).&#xD;
&#xD;
          -  Subjects receiving bisphosphonates or other approved bone-targeting therapy (e.g.,&#xD;
             denosumab) must be on a stable dose for at least 28 days prior to the start of study&#xD;
             treatment.&#xD;
&#xD;
          -  Demonstrate adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Biologic anti-cancer therapy within 28 days prior to the start of study treatment.&#xD;
&#xD;
          -  Use of hormonal agents with anti-tumor activity against prostate cancer within 28 days&#xD;
             prior to the start of study treatment.&#xD;
&#xD;
          -  Use of herbal products or alternative therapies that may decrease PSA levels or that&#xD;
             may have hormonal anti-prostate cancer activity within 28 days prior to the start of&#xD;
             study treatment or plans to initiate during the study.&#xD;
&#xD;
          -  Intervention with any chemotherapy, investigational agents, or other anti-cancer drugs&#xD;
             within 28 days of the first dose of study treatment.&#xD;
&#xD;
          -  Use of radium-223 dichloride or other radioligand/radiopharmaceutical within 28 days&#xD;
             prior to the start of study treatment.&#xD;
&#xD;
          -  Received limited-field palliative bone radiotherapy &gt;5 fractions and/or any&#xD;
             radiotherapy within 2 weeks prior to the start of study treatment.&#xD;
&#xD;
          -  Received a blood transfusion within 28 days of hematologic screening labs.&#xD;
&#xD;
          -  Known intra-cerebral disease or brain metastasis unless adequately treated and stable&#xD;
             for the last 28 days before signing of informed consent.&#xD;
&#xD;
          -  Spinal cord compression.&#xD;
&#xD;
          -  Diagnosis of another clinically significant malignancy within the previous 3 years&#xD;
             other than curatively treated non-melanomatous skin cancer or superficial urothelial&#xD;
             carcinoma and other in situ or non-invasive malignancies.&#xD;
&#xD;
          -  Gastrointestinal issues affecting absorption.&#xD;
&#xD;
          -  Significant cardiovascular disease.&#xD;
&#xD;
          -  Known history of seizure or conditions that may pre-dispose them to seizure, including&#xD;
             brain injury with loss of consciousness, transient ischemic attack within the past 12&#xD;
             months, cerebral vascular accident, brain metastases, and brain arteriovenous&#xD;
             malformation.&#xD;
&#xD;
          -  Concurrent disease or any clinically significant abnormality.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to any components of the formulation used for&#xD;
             EPI-7386 or enzalutamide.&#xD;
&#xD;
          -  Use of compounds known to be strong inducers and strong inhibitors of CYP3A and CYP2C8&#xD;
             within 14 days of the first dose of study drug.&#xD;
&#xD;
          -  Use of narrow therapeutic index sensitive CYP2C8 or sensitive substrates for CYP3A and&#xD;
             CYP2B6.&#xD;
&#xD;
          -  Use of granulocyte colony stimulating factor within 7 days prior to screening&#xD;
             laboratories.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen Villaluna</last_name>
    <phone>650-449-8400</phone>
    <email>kvillaluna@essapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology Oncology Associates of the Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Lakes Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

